These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16093832)

  • 1. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
    Sfikakis PP; Boletis JN; Tsokos GC
    Curr Opin Rheumatol; 2005 Sep; 17(5):550-7. PubMed ID: 16093832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
    Marks SD; Tullus K
    Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 6. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
    Sabugo F; Llanos C; Soto L; Gutiérrez J; Cuchacovich M
    Rev Med Chil; 2005 Jun; 133(6):681-4. PubMed ID: 16075133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Chambers SA; Isenberg D
    Lupus; 2005; 14(3):210-4. PubMed ID: 15807198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Connective tissue diseases: The conundrum of B cell depletion in SLE.
    Sanz I
    Nat Rev Rheumatol; 2009 Jun; 5(6):304-5. PubMed ID: 19491910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
    Walsh M; Jayne D
    Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
    Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
    Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
    Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
    Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y
    J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLE - Rituximab in lupus.
    Eisenberg R
    Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
    Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.